PET shows effectiveness of gantenerumab for Alzheimer's disease

10/10/2011 | AuntMinnie.com (free registration)

PET with carbon-11-labeled Pittsburgh Compound B showed that treatment with an antibody called gantenerumab can reduce the levels of amyloid-beta plaque in the brains of patients with Alzheimer's disease, according to a Swiss study published in the Archives of Neurology. The reduction in the plaque was directly related to the size of the treatment dose, the researchers said. "Additionally, our findings in the placebo-treated patients support previous reports indicating that amyloid load continues to increase in many patients with mild-to-moderate Alzheimer's disease," the researchers added.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC